Biomedicine

Cell Medicine News
For the Benefit of Patients and Clinicians

Stem Cell trends, product safety

Journal of Biomedicine, Somata Genesis, Inc. — To support patients, researchers, clinical professionals and funders, we curate and enrich research with high-quality data and analytics and help customers address challenges at every stage of the research journey.

  • Mechanisms of Self-Directed Immune Pathology

    Autoimmune disease arises from the breakdown of immunological self-tolerance, resulting in adaptive immune responses directed against host tissue. This paper examines three core mechanisms underlying this process: autoreactive lymphocyte activation via molecular mimicry, the inverse regulatory relationship between immune tolerance and tumor surveillance, and the pathophysiology of virus-associated vascular injury. Across all three domains, the…

    Read more..

  • The Physiological and Biophysical Infeasibility of Intranasal and Nebulized Cellular Therapies

    Recent trends in unregulated regenerative medicine have seen the emergence of “spa” clinics marketing the intranasal administration or nebulization of live stem cells—predominantly mesenchymal stem cells (MSCs)—and their derived extracellular vesicles (EVs/exosomes). This paper deconstructs the biophysical, mechanical, and physiological barriers that render these delivery modalities fundamentally unviable. We demonstrate that the shear stress of…

    Read more..

  • Rebranding of Uncharacterised MSC as “MUSE” Cell Therapies

    A Critical Commentary The rapid commercialization of regenerative medicine has led to a noticeable surge in unregulated cross-border wellness clinics offering uncharacterized cellular products for degenerative conditions. Recently, a marketing trend has emerged wherein standard Mesenchymal Stromal Cells (MSCs)—often derived from unexpanded or crudely processed umbilical cord matrix (Wharton’s Jelly)—are branded and sold as Multilineage-differentiating…

    Read more..

  • Challenges in the Intravenous Administration of Cellular Products

    Intravenous (IV) treatments are often seen as affordable options because they typically do not involve hospitals, doctors, or medicolegal liability. However, they may introduce risky experimental products into the bloodstream, often labeled as “stem cells,” which the provider claims are safe. It raises the question: why do some patients, who are concerned about the side…

    Read more..

  • Mannitol dose not physically open the blood brain barrier

    This is a common misconception used by some spa clinics to promote their cellular treatments while downplaying the limitations of their inexpensive administration methods. Mannitol, a diuretic, disrupts osmotic balance (osmoregulation) to facilitate the movement of soluble chemicals. However, it does not increase the permeability of the endothelial membrane, meaning it does not assist cellular…

    Read more..

  • Risks associated with East Asian Human Cellular products

    An increasing number of East Asian clinics at medical tourism destinations are offering affordable cellular therapies targeted at Western tourists. As the demand for unregulated therapies rises globally, many entities now provide cellular products sourced from locally harvested human tissues, the procurement and refinement processes of which are often unknown to both the provider and…

    Read more..